Last reviewed · How we verify
Atrasentan high dose group
Atrasentan is an endothelin receptor antagonist that blocks the action of endothelin-1, a potent vasoconstrictor.
Atrasentan is an endothelin receptor antagonist that blocks the action of endothelin-1, a potent vasoconstrictor. Used for Hypertension.
At a glance
| Generic name | Atrasentan high dose group |
|---|---|
| Sponsor | AbbVie (prior sponsor, Abbott) |
| Drug class | Endothelin receptor antagonist |
| Target | Endothelin receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 2 |
Mechanism of action
By blocking endothelin-1, atrasentan reduces vascular resistance and lowers blood pressure. This mechanism is particularly relevant in the treatment of hypertension and related cardiovascular conditions.
Approved indications
- Hypertension
Common side effects
- Edema
Key clinical trials
- Reducing Residual Albuminuria in Subjects With Diabetes and Nephropathy With Atrasentan (PHASE2)
- A Prospective, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy and Safety of Atrasentan, Including Thoracic Bioimpedance, in Type 2 Diabetic Subjects With Nephropathy (PHASE2)
- Evaluate the Efficacy and Safety of Once Daily Administration of Atrasentan Tablets (Low and High) Compared to Placebo in Reducing Residual Albuminuria in Type 2 Diabetic Patients With Nephropathy Who Are Treated With the Maximum Tolerated Labeled Dose of a Renin Angiotensin System (RAS) Inhibitor (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Atrasentan high dose group CI brief — competitive landscape report
- Atrasentan high dose group updates RSS · CI watch RSS
- AbbVie (prior sponsor, Abbott) portfolio CI